Muhammad Absar, “CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML”, J Popl Ther Clin Pharmacol, vol. 29, no. 02, pp. 311–320, Feb. 2022, doi: 10.53555/jptcp.v29i02.4161.